Abstract
AbstractBackgroundCanada has high immunoglobulin (IG) product utilization, raising concerns about appropriate utilization, cost and risk of shortages. Currently, there is no national set of standardized IG guidelines, and considerable variations exist among the existing provincial guidelines. The aims of this study were: (1) to compare the existing Canadian provincial guidelines on the use of IG products to identify their consistencies and differences and (2) to examine the existing research in Canada on IG supply and utilization following the establishment of IG guidelines to understand the scope of research and pinpoint the gaps.MethodsA comparative analysis accounted for the differences across provincial IG guidelines. We highlighted similarities and differences in recommendations for medical conditions. A scoping review of citations from MEDLINE, PubMed, Scopus and Embase databases was conducted for studies published from January 01, 2014, to April 12, 2023.ResultsWhile provincial guidelines represented a considerable overlap in the medical conditions delineated and relatively uniform dose calculations, numerous differences were observed, including in recommendation categories, provision of pediatric dosing, and divergent recommendations for identical conditions based on patient demographics. The scoping review identified 29 studies that focused on the use of IG in Canada. The themes of the studies included: IVIG utilization and audits, the switch from IVIG to SCIG, patient satisfaction with IVIG and/or SCIG, the economic impact of self-administered SCIG versus clinically administered IVIG therapy, and the efficacy and cost-effectiveness of alternative medications to IG treatment.ConclusionThe differences in guidelines across provinces and the factors influencing IVIG/SCIG use, patient satisfaction, and cost savings are highlighted. Future research may focus on clarifying costs and comparative effectiveness, exploring factors influencing guideline adherence, and evaluating the impact of updated guidelines on IG use and patient outcomes.
Funder
Canadian Blood Services
Mitacs
Natural Sciences and Engineering Research Council of Canada
Calgary Foundation
Publisher
Springer Science and Business Media LLC
Subject
Pulmonary and Respiratory Medicine,Immunology,Immunology and Allergy
Reference59 articles.
1. Arumugham VB, Rayi A. Intravenous Immunoglobulin (IVIG). StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC.; 2022. https://www.ncbi.nlm.nih.gov/books/NBK554446/].
2. Perez EE, Orange JS, Bonilla F, Chinen J, Chinn IK, Dorsey M, et al. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol. 2017;139(3S):S1–46. https://doi.org/10.1016/j.jaci.2016.09.023.
3. Harding SR, Lazarus A. Chapter 4: Immune globulin products. In: Khandelwal A, Abe T, editors. Canadian Blood Services' Clinical Guide to Transfusion online edition 2018. https://professionaleducation.blood.ca/en/transfusion/clinical-guide/immune-globulin-products (Accessed 01 Feb 2023).
4. Home-Based Subcutaneous Infusion of Immunoglobulin for Primary and Secondary Immunodeficiencies: A Health Technology Assessment. Ontario health technology assessment series. 2017; 17(16): 1–86.
5. Expert Panel on immune globulin product supply and related impacts in Canada. Protecting Access to Immune Globulins for Canadians. Government of Canada Publications, 2018. https://publications.gc.ca/collections/collection_2018/sc-hc/H22-4-12-2018-eng.pdf (Accessed 01 Feb 2023).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献